To the Editor: In their Perspective article in this issue of the Journal, Hauser and Almquist¹ discuss issues involved in the testing of implantable cardioverter–defibrillators (ICDs). The authors contend that “the decision by the FDA [Food and Drug ...

To the Editor: The rate of 1.3% for advanced adenoma detected approximately 5 years after a negative colonoscopy, is indeed low, as Imperiale et al. report (Sept. 18 issue).¹ The rate for detection of any adenoma was 16.0%. What is striking is the low ...

To the Editor: San Miguel et al. (Aug. 28 issue)¹ state that the standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone. In the light of recent studies,²,³ we do not think this ...

To the Editor: Contrary to the statement by Kim et al. (Sept. 4 issue)¹ in their article on the prognostic effect of hyponatremia on the survival of patients on the liver-transplant waiting list, organ allocation should not be decided solely on the basis ...

To the Editor: Karim et al. (Sept. 11 issue)¹ report on three nonsynonymous nucleotide changes in NHERF1 (also called SLC9A3R1) — at p.L110V, p.R153Q, and p.E225K — which were found in 4 of 92 unrelated patients with nephrolithiasis or osteopenia. The ...

This case demonstrates the potential for using whole-ovary transplantation between monozygotic twins who are discordant for premature ovarian failure, in order to restore fertility in the affected twin.

To the Editor: Although artemisinins are potent and rapidly acting antimalarial drugs, their widespread use for treating patients with Plasmodium falciparum malaria raises the question of emerging drug resistance.¹,² Artemisinin monotherapy should not be ...